TP53 and non-small cell lung carcinoma: Clearly, SRA737 treatment of the TP53 MUT H23 NSCLC and HT29 CRC cells led to significant increases in ACA-detectable strand break DNA damage compared to the TP53 WT A549 NSCLC & HCT116 CRC cells (Figure 1); this being consistently and significantly higher for the highest concentration of SRA737 used, for both TP53 MUT cells.